Compare OMER & IGIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OMER | IGIC |
|---|---|---|
| Founded | 1994 | 2001 |
| Country | United States | Jordan |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 996.3M |
| IPO Year | 2008 | 2019 |
| Metric | OMER | IGIC |
|---|---|---|
| Price | $13.29 | $23.89 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | $27.50 | ★ $30.00 |
| AVG Volume (30 Days) | ★ 1.2M | 64.4K |
| Earning Date | 11-16-2026 | 11-03-2026 |
| Dividend Yield | N/A | ★ 6.08% |
| EPS Growth | ★ 98.15 | N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $29,868,000.00 | N/A |
| Revenue This Year | N/A | $4.98 |
| Revenue Next Year | $66.13 | $2.89 |
| P/E Ratio | $107.77 | ★ $9.05 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.70 | $22.14 |
| 52 Week High | $21.24 | $29.59 |
| Indicator | OMER | IGIC |
|---|---|---|
| Relative Strength Index (RSI) | 30.78 | 43.85 |
| Support Level | $9.45 | $23.18 |
| Resistance Level | $19.68 | $25.24 |
| Average True Range (ATR) | 0.92 | 0.69 |
| MACD | -0.45 | 0.02 |
| Stochastic Oscillator | 8.90 | 33.76 |
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.
International General Insurance Holdings Ltd is an international specialty insurance and reinsurance group. It underwrites a diversified portfolio of specialty risks including energy, property, construction and engineering, ports and terminals, general aviation, political violence, professional lines, financial institutions, marine, contingency and treaty reinsurance. The company's operating segments include Specialty Longtail, Specialty Short tail and Reinsurance. The majority of revenue is derived from the Specialty Short-tail segment, which comprises business lines with underwriting risks assumed in the form of property and specialty lines insurance and of short-term nature with respect to related claims.